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OBJECTIVE: To determine if the public consumption of
herbs, vitamins, and supplements changes in light of
emerging negative evidence.
METHODS: We describe trends in annual US sales of
five major supplements in temporal relationship with
publication of research from three top US general
medical journals published from 2001 through early
2006 and the number of news citations associated with
each publication using the Lexus-Nexis database.
RESULTS: In four of five supplements (St. John’s wort,
echinacea, saw palmetto, and glucosamine), there was
little or no change in sales trends after publication of
research results. In one instance, however, dramatic
changes in sales occurred following publication of data
suggesting harm from high doses of vitamin E.
CONCLUSION: Results reporting harm may have a
greater impact on supplement consumption than those
demonstrating lack of efficacy. In order for clinical trial
evidence to influence public behavior, there needs to be
a better understanding of the factors that influence the
translation of evidence in the public.
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BACKGROUND
Herbs, vitamins, and other dietary supplements are popular
self-care products in the US.
1 In the last decade, the National
Institutes of Health has devoted nearly $2 billion to studying
complementary and alternative medicine (CAM),
2 including
several major clinical trials on herbs, vitamins, and supple-
ments (hereafter “supplements”).
3–5 In addition, other federal
agencies have sponsored research synthesizing evidence from
supplement trials over this same time period.
6
The social value of clinical research derives from its potential
to inform improvements in medical practice and public
health.
7–9 For example, in the wake of evidence from large trials
demonstrating harm from hormone replacement therapy and
alpha-blockers, use of these products declined.
10,11 It is an
open question whether research evaluating the safety and
efficacy of supplements makes a comparable practical differ-
ence, especially as their use is often not mediated by a
healthcare provider. Especially in the domain of supplements,
whether and how findings published in medical journals make
their way into popular information channels is unknown.
Indeed, some commentators have challenged the public invest-
ment in CAM research altogether on the assumption that the
results are unlikely to have any impact on CAM use.
12 Here we
briefly describe supplement sales trends for five popular
supplements published in the general medical literature in
recent years and examine whether publication is temporally
associated with changes in the public’s use of these agents.
METHODS
Using Pubmed, we identified key supplements that had been
the subject of at least one study published in a major US
general medical journal (New England Journal of Medicine,
Annals of Internal Medicine, or JAMA) from 2001 through
early 2006: St. John's Wort, vitamin E, echinacea, saw
palmetto, and glucosamine/chondroitin. We focused on these
medical journals because news services tend to emphasize the
articles in the major publications, and the number of news
stories was our proxy indicator for public exposure to medical
news. These supplements are some of the most commonly
used in the US, and they represent a diverse range of
supplement consumers and clinical conditions.
We assumed that if the research was having an impact, the
sales of a supplement would change in a manner commensurate
with the evidence in the subsequent annual sales trends. We
acquired annual sales data through 2006 for studied supple-
mentsfrom theNutritionBusinessJournal,amonthlyexecutive
newsletter that defines and tracks industry trends in the sales of
nutritional products and supplements for the entire US market.
In addition, we assumed that clinical research makes its way to
the public by means of the popular press. Therefore, we
determined the total number of US news and wire stories for
each study for the period of 1 week prior to publication through
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14952 months after publication using the Lexis-Nexis database. We
plotted annual sales in $US (y-axis) versus time (x-axis) and
annotated graphs with time points indicating study publication
dates, looking for changes in sales trends in the year immedi-
ately subsequent to the date of publication.
To determine the significance of temporal associations with
publication, we fit a linear slope to the data for all time points
prior to the publication date, calculated the 95% confidence
interval (CI) around that slope, andthen extrapolated forall time
points after the publication date by extending the line and the
corresponding CI lines. We then plotted expected and observed
saleslines inordertodeterminewhether theobserved data post-
publication fell outside of an expected range. Only those actual
sales that fell outside of the 95% expected sales interval prior to
publication were considered significant.
RESULTS
Sales trends for each of the five supplements in relationship to
research publication are presented in Figure 1. The number of
press citations for each study within 2 months of publication
ranged from 39 to 71 (Table 1).
St. John’s Wort (Hypericum Perforatum)
St. John's wort plant extract has been used to treat mild to
moderate symptoms of depression.
13–15 US sales of St. John’s
wort peaked at nearly $315 million in 1998. In 2000 concerns
were raised about the safety of St. John’s wort because of its
potential to interfere with anti-retroviral medications.
16,17 Two
large studies of St. John's wort for major depression published
in 2001 and 2002 cast doubt on its effectiveness for major
depression.
3,18 These two studies were covered in 63 and 57
new stories respectively around the time of publication.
Changes in sales after publication of the study results in April
2001 and April 2002 were gradual and consistent with the
trend prior to publication.
Vitamin E (alpha-tocopherol)
Vitamin E is a fat-soluble anti-oxidant that may mitigate
oxidative stress linked to cancer and cardiovascular disease.
In January 2005 a meta-analysis of major vitamin E trials
raised concerns about higher mortality rates among study
participants who took >800 IU of Vitamin E per day.
19 In
March and July of 2005, two additional studies reported little
or no effect of vitamin E in preventing cancer and cardiovas-
cular disease.
20,21 These studies were mentioned in 67, 40,
and 71 news stories respectively for a total of 178 citations in
the wake of these studies. These citation numbers included the
two highest number of citations among all supplements we
examined and together represent 50–300% greater news
citations for a given sales year than any other supplement.
After the 2005 publications, annual sales dropped sharply
(down 33%) from previous sales levels and continued to decline




Echinacea angustafolia and purpurea, two species of purple
cone flower, have been used to treat cold symptoms and upper
respiratory infections. Two prominent studies, one investigating
Echinacea purpurea published in December 2003 and one
investigating Echinacea angustafolia published in July 2005,
showed no benefit in treatment and prevention of colds.
4,22 The
only significant side effects were an allergic rash in children.
These studies were mentioned in 39 and 55 news stories
respectively. US annual sales of all echinacea products exceeded
$200 million in 2000 and 2001. From 2003 to 2004, sales
dropped modestly from $177 million to $153 million (down
14%). Sales between 2004 and 2005 reached a plateau and then
dropped further in 2006 from $154 to $129 million (down 16%).
These modest declines were not significant, suggesting no
substantial immediate impact of the research on sales.
Saw Palmetto
The ripe fruit of the saw palmetto plant (serenoa repens)i s
used to treat urinary symptoms related to benign prostatic
hyperplasia (BPH).
23 The largest US study to date published in
February 2006 reported that while well tolerated, saw palmetto
was no better than placebo in improving symptoms of BPH.
24
US annual sales of saw palmetto peaked in 2003 at $145
Figure 1. Annual trends in sales of selected supplements in the US from 2000–2006 with dates of major negative publications.
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around the time of publication. Annual sales dropped only
slightly from $137 to $134 million between 2005 and 2006
(down 2.5%).
Glucosamine and Chondroitin
Supplemental glucosamine alone or taken in combination with
chondroitin has gained popularity for treating symptoms of
osteoarthritis. In February 2006, results from a large federally
funded trial
5 showed that glucosamine alone or in combination
with chondroitin did not improve symptoms of osteoarthritis
more than placebo. However, a pre-planned secondary analy-
sis suggested that the glucosamine/chondroitin combination
was more beneficial than placebo in a subgroup with moder-
ate-to-severe osteoarthritis. There were no serious adverse
events reported. This study was mentioned in 58 news stories
around the time of publication. After publication of the study
sales did not substantially change.
DISCUSSION
Whether and to what extend supplement research makes a
difference to consumers is a multi-faceted public health
research question that this study only begins to assess. When
supplement research results report harm, they may be more
influential to consumers and their physicians than results
reporting lack of efficacy. Conversely, when research shows
supplements to be safe but not necessarily effective, there may
be little or no influence in public consumption. The case of
vitamin E suggests it is possible for negative evidence revealing
adverse effects from clinical research to cause dramatic
declines in the consumption of supplements. Between 2004
and 2005 sales dropped dramatically (33%) comparable to
declines in hormone replacement therapy after publication of
research by the Women’s Health Initiative.
11
However, in the case of echinacea and saw palmetto, where
the products were shown to be relatively safe but no better
than placebo, declines in sales were more modest and
consistent with secular sales trends. For glucosamine, publi-
cation of mixed outcome results was associated with no
appreciable marginal change in product sales. And for St.
John's wort, reports regarding drug interactions predating
publication of the large studies in 2001 and 2002, and smaller
studies showing efficacy around the same time and subse-
quently
25,26, may have prevented those studies from having
any additional marginal impact on sales trends.
For this analysis we assumed that press exposure was an
important mediator by which supplement trials might influ-
ence public behavior. The prominent studies we report here
varied little in their number of Lexus-Nexis citations associated
with their publication. However, vitamin E had the largest
number of citations (71) and the highest total of citations (178),
which exceeded the total of citations for the other four
supplements by 50–300 percent. How the media covers a
study and how that coverage does or does not persist could not
be captured using our simple methods.
Multiple other factors not measured in this study likely
contribute to whether results from clinical research on supple-
ments have an impact. It is important to acknowledge that the
number and significance of prior positive studies may influ-
ence whether sales after a single publication decline. For
instance, if a given supplement has no side-effects and
multiple previous studies showing potential benefit, one might
expect minimal declines in sales after one negative result.
Multiple studies on the same supplement published within
months of each other, as was the case in vitamin E, may have
promoted a stronger association with sales changes not seen in
single studies. Furthermore, consumers of different supple-
ments may vary their response to the evidence based on the
specific purpose of the supplement, the type of supplement,
and the pharmacological alternatives. The purposes for which
vitamin E are taken (prevention) differ from saw palmetto and
St. John’sw o r t( c h r o n i cs y m p t o m s )o re c h i n a c e a( a c u t e
symptoms). Furthermore, vitamin E may be more likely to be
recommended by physicians than the other supplements,
making them more concerned about advising their patients
in light of the emerging safety data.
The type of supplement may make a difference too. As
suggested by Nahin,
27 consumers who use vitamin and
mineral supplements had differences in their characteristics.
They found that vitamin or mineral use was associated with
female sex, white race, non-smoking, more years of schooling,
difficulty walking, a history of osteoporosis, and reading health
magazines, whereas non-vitamin, non-mineral dietary supple-
ment use was primarily associated with residing in California
and having difficulty with muscle strength. Accordingly, these
different consumer groups may respond differently to new
evidence. Finally, even if clear persuasive research were
optimally reported and disseminated, consumers would still
face persistent challenges in interpreting marketing messages
they receive regarding supplements. For instance, in the wake
of the glucosamine trial, manufacturers highlighted the sec-
ondary outcomes of the trial showing benefit, while excluding
the results showing placebo equivalence. Consumers may be
exposed to multiple sources of information including alterna-
tive medicine publications that may interpret the same data
differently. Thus, achieving a public health impact for research
on supplements may be particularly challenging in light of
their current regulatory status and popular appeal.
Our approach has limitations. Temporal associations from
sales trends cannot establish causation. At best our approach
represents a quasi-experimental design in which the exposure
Table 1. Supplement studies published in major general medical
journal




18 JAMA. 2001;285(15):1978–86. 4/01 63
3 JAMA, 2002; 287:1807–1814. 4/02 57
Vitamin E
19 Ann Intern Med 2005; 142:37–46. 11/04 (epub) 67
20 JAMA 2005; 293:1338–1347. 3/05 40
21 JAMA 2005; 294(1): 56–65. 7/05 71
Echinacea
22 JAMA 2003;290(21): 2824–2830. 12/03 39
4 New Eng J Med 2005; 353(4): 341–348. 7/05 55
Saw palmetto
24 New Eng J Med 2006;354:557–566. 2/06 45
Glucosamine/chondroitin
5 New Eng J Med, 2006;354:795–808. 2/06 58
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internal validity of making accurate causal inferences related
to the exposure.
28 We did not directly measure whether media
coverage actually reached the consumers of interest, nor did
we measure public attitudes toward the research results. And
it is difficult to say a priori how much individual studies ought
to change supplement consumption. It may not be reasonable
to expect every individual study to show demonstrable market
impact. In fact, it often takes a long-term clinical research
investment in order for the weight of the evidence to reach a
compelling “tipping point”, as seems to be the case with
vitamin E. Thus, achieving a significant public health impact
in supplement research may require a longer, more sustained
research time horizon than some had initially anticipated.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduc-
tion in any medium, provided the original author(s) and source
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CONCLUSION
Achieving public health impact should be a goal for all clinical
research. Examining the potential public impact of clinical
research publication on supplement consumption illustrates
some of the challenges in translating research evidence into
public health impact. Studies showing harm may more
dramatically influence public behavior than studies only
showing lack of efficacy. The impact of major studies indicating
benefit remains unknown. To enhance the translational im-
pact of supplement research, it may be fruitful to invest a
small portion of supplement research funding to better
understand and address the factors involved in public respon-
siveness to evidence from clinical research.
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